Brief: Brainstorm Cell Therapeutics Announces FDA Advisory Committee Meeting To Review Nurown Biologics License Application
06/06/2023 11:03
June 6 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS ANNOUNCES FDA ADVISORY
COMMITTEE
MEETING TO REVIEW NUROWN® BIOLOGICS LICENSE APPLICATION
SCHEDULED FOR SEPTEMBER 27, 2023
* BRAINSTORM CELL THERAPEUTICS INC - PDUFA TARGET ACTION
DATE SET
TO OCCUR BY DECEMBER 8, 2023
Source text for Eikon: ID:nPn5lbtRca
Further company coverage: BCLI.O
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview